{
    "nctId": "NCT04998682",
    "briefTitle": "Prospective Evaluation of Targeted Axillary Dissection (TAD)",
    "officialTitle": "TAD: Prospective Evaluation of Targeted Axillary Dissection After Neoadjuvant Systemic Therapy in Patients With Breast Cancer With Advanced Nodal Disease at Diagnosis",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "False Negative Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women or men greater than or equal to 18 years.\n* Histologically confirmed invasive adenocarcinoma of the breast.\n* Clinical T0-4 N2-3 M0 at diagnosis (American Joint Committee on Cancer, 7th Edition)\n\n  * Assessment for cN2 disease will be performed by clinical exam and imaging. Patients should have pathologic level 1 and/or 2 axillary lymph nodes which are fixed/matted on physical exam.\n  * Cross-sectional imaging will be used to identify advanced nodal disease involving the axilla, infraclavicular, supraclavicular, and internal mammary regions, cN3 disease.\n* Patients must have biopsy proven involvement of the axillary lymph nodes.\n* Receipt of standard multiagent chemotherapy +/- targeted therapy based on tumor subtype.\n* Candidate for surgical management of breast cancer.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* History of allergic reactions or hypersensitivity to radioactive lymph node mapping agents or blue dye.\n* Pregnancy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}